ProxiGene
Genomics Division of HealthSpan360

PRECISION GENOMICS
PROVIDER-ORDERED · LDT

Pharmacogenomics Panel

Genotype-guided prescribing intelligence, delivered as clinical action — not raw data.

34	14	CPIC
genes, HLA & PD markers	therapeutic areas	DPWG · FDA · PharmGKB aligned

COMPREHENSIVE COVERAGE

34 pharmacogenes, HLA loci & pharmacodynamic markers

PHASE I METABOLISM
CYP2D6 CYP2C19 CYP2C9 CYP3A4 CYP3A5 CYP2C8 CYP2B6 CYP2E1 CYP4F2

PHASE II METABOLISM
UGT1A1 UGT2B7 TPMT NUDT15 NAT2 DPYD GSTM1 GSTP1

TRANSPORTERS
SLCO1B1 ABCG2

HLA / IMMUNE
HLA-B*57:01 HLA-B*58:01 HLA-B*15:02 HLA-A*31:01

PHARMACODYNAMIC
COMT OPRM1 HTR2A IFNL3 VKORC1

OTHER CLINICAL
CFTR G6PD RYR1 CACNA1S F2 F5

THE DECISION-SUPPORT DIFFERENCE

More than a gene list — a decision-support layer

Clinician Action Summary
A triaged dashboard opens every report — the interactions that need attention, first.

Severity tiering
Findings ranked major or moderate, with a clear alternate-drug vs alternate-dosing call.

Organized by therapeutic area
Sorted across 14 clinical categories, in the context you prescribe in.

CPIC-aligned alternatives
Flagged drugs come with guideline-consistent alternatives and dosing guidance.

Full transparency
Every genotype and allele interrogated is shown, including no-action calls.

Evidence on every card
Each finding carries its CPIC / DPWG / FDA / PharmGKB level-of-evidence and citation.

THE PROXIGENE DIFFERENCE

Where many reports stop at a genotype and a phenotype label, ProxiGene carries the finding through to a prescribing decision.

ProxiGene PGX Panel · A HealthSpan360 Product · HealthSpan360 LLC
Provider-ordered · Performed in a CLIA-certified laboratory (CLIA #45D2326543)

Guideline-anchored to CPIC · DPWG · FDA · PharmGKB (PharmVar nomenclature). Laboratory-developed test, not FDA-cleared or approved (clearance not required for LDTs); it informs, and does not replace, the prescriber's clinical judgment. orders@hs360.co · hs360.co

WHY IT MATTERS

Benefits across the care pathway

Better prescribing decisions

- Anticipate high-severity risks, including HLA-linked hypersensitivity, before the first dose.
- Inform drug and dose selection up front, reducing trial-and-error.
- Surface metabolizer status that may affect response or tolerability.

Simple to order, easy to act on

- One sample; one structured, severity-triaged report.
- The Clinician Action Summary surfaces what needs attention first.
- Tested once, the result stays in the record and informs future prescribing.

Value that compounds

- May reduce repeat visits and medication switches from failed trials.
- A single preemptive result informs prescribing across many future medications.
- Guideline-anchored evidence supports formulary and stewardship goals.

WHO ORDERS PROXIGENE

Actionable across specialties

Primary Care & Internal Medicine
CYP2C19 (PPIs, clopidogrel) · SLCO1B1 (statins) · CYP2D6 / CYP2C19 (antidepressants)

Psychiatry & Behavioral Health
CYP2D6 & CYP2C19 (antidepressants, antipsychotics) · HTR2A · COMT · OPRM1

Cardiology
CYP2C19 (clopidogrel) · CYP2C9 · VKORC1 · CYP4F2 (warfarin) · SLCO1B1 (statins) · F2 · F5

Pain Management & Anesthesiology
CYP2D6 (codeine, tramadol) · OPRM1 · COMT · RYR1 · CACNA1S (malignant hyperthermia)

Oncology & Hematology
DPYD (fluoropyrimidines) · TPMT · NUDT15 (thiopurines) · UGT1A1 (irinotecan) · CYP2D6 (tamoxifen)

Gastroenterology
CYP2C19 (PPIs) · TPMT · NUDT15 (azathioprine, 6-MP)

Infectious Disease
HLA-B*57:01 (abacavir) · IFNL3 (HCV therapy) · CYP2B6 (efavirenz) · G6PD

Neurology
CYP2C9 & HLA-B*15:02 (carbamazepine, phenytoin) · HLA-A*31:01 · CYP2D6

Bring genotype-guided prescribing into your practice.

Provider-ordered · one sample · results returned to the ordering clinician.

Guideline-anchored to CPIC · DPWG · FDA · PharmGKB (PharmVar nomenclature). Laboratory-developed test, not FDA-cleared or approved (clearance not required for LDTs); it informs, and does not replace, the prescriber's clinical judgment. orders@hs360.co · hs360.co